The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: A rapid and systematic review

Health Technology Assessment

Volumn 5, Issue 2, 2001, Pages

  Stewart, A ^a   Sandercock, J ^a   Bryan, S ^a   Hyde, C ^a   Barton, P M ^a   Fry Smith, A ^a   Burls, A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RILUZOLE;

ABDOMINAL PAIN; ASTHENIA; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEADACHE; HEALTH ECONOMICS; HUMAN; INCIDENCE; LICENSING; LIFE EXPECTANCY; MOTOR NEURON DISEASE; NATIONAL HEALTH SERVICE; NAUSEA AND VOMITING; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SOMNOLENCE; STATISTICAL MODEL; SURVIVAL; SYMPTOM; TABLET; TACHYCARDIA; TRACHEOSTOMY; TREATMENT OUTCOME; VALIDATION PROCESS; VERTIGO;

EID: 0035207059     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta5020     Document Type: Review

References (79)

1. Clinical features and diagnosis of amyotrophic lateral sclerosis
2. Clinical review; Science, medicine and the future: Motor neurone disease
3. Defining optimal management in ALS: From symptoms to announcement
4. Diagnosing motor neurone disease
5. An algorithm for ALS diagnosis and management
6. Current treatment pathways in ALS: A South American perspective
7. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial "Clinical limits of amyotrophic lateral sclerosis" Workshop contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
8. What are the implications of early diagnosis? Maintaining optimal health as long as possible
9. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide
10. The prognosis of adult-onset motor neuron disease: A prospective study based on the Scottish motor neurone disease register
11. Prognostic indicators of survival in ALS
12. Clinical statistics in 515 fatal cases of motor neuron disease: Determinants of course
13. Motor neurone disease: Some hope at last for respiratory complications
14. Motor neurone disease: A hospice perspective
15. Death from motor neurone disease can be peaceful
16. Riluzole may help survival in motor neurone disease
17. Ethnic differences in MND: A case control study
18. Decreased striatal dopamine-receptor binding in sporadic amyotrophic lateral sclerosis: Glutamate hyperactivity?
19. Motor neuron disease in England and Wales, 1959-1979
20. Riluzole - What is its impact in our treatment and understanding of amyotrophic lateral sclerosis?
21. Riluzole for amyotrophic lateral sclerosis
22. The pharmacology and mechanism of action of riluzole
23. Excitotoxicity in amyotrophic lateral sclerosis
24. The tolerability and adverse event profile of riluzole
25. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology: ALS practice parameters task force
26. Service provision for patients with ALS/MND: A cost-effective multidisciplinary approach
27. Current treatment pathways in ALS: A European perspective
28. Press release: Aventis announces unaudited 1999 sales
29. Cochrane reviewers' handbook 4.0
30. Identifying relevant studies for systematic reviews
31. A confirmatory dose-ranging study of riluzole in ALS
32. A controlled trial of riluzole in amyotrophic lateral sclerosis
33. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
34. Comprehensive medical report
35. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: Double-blind placebo-controlled study in Japan
36. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
37. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis
38. Recovery of N-acetylaspartate on corticomotor neurons of patients after riluzole therapy
39. Reduction in mortality from ALS with riluzole
40. Open label study of riluzole for the treatment of amyotrophic lateral sclerosis
41. The effect of riluzole in amyotrophic lateral sclerosis: A study with cortical stimulation
42. Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
43. Intérìts d'une base de données informatisée dans le diagnostic et le suivi de patients atteints de la sclérose latérale amyotrophique
44. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND)
45. Subgroup analysis and other (mis) uses of baseline data in clinical trials
46. ALS/MND and the perspective of health economics
47. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis
48. Cost effectiveness of riluzole in amyotrophic lateral sclerosis
49. Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis
50. Modelling valuations for EuroQol health states
51. Economic burden of amyotrophic lateral sclerosis in the United Kingdom
52. I deserve a life, too
53. The case for physician-assisted suicide and active euthanasia in amyotrophic lateral sclerosis
54. Factors influencing a patient's decision regarding riluzole: An early experience
55. The ALS patient care database: Goals, design, and early results. ALS C.A.R.E. Study Group
56. The development and validation of the Amyotrophic Lateral Sclerosis Quality of Life Scale
57. The European amyotrophic lateral sclerosis health profile study
58. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: The ALSAQ-40
59. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials
60. The administration of guanidine in amyotrophic lateral sclerosis
61. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
62. Riluzole®. Volume 1: Follow-up measures